Addex Therapeutics Ltd (ADXN)

Addex Therapeutics Income Statement

Financials in millions CHF. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019	2018	2017
Revenue	1.65	1.44	3.15	3.88	2.83	6.7	0.5
Revenue Growth (YoY)	13.99%	-54.18%	-18.71%	36.89%	-57.72%	1240.82%	-
Gross Profit	1.65	1.44	3.15	3.88	2.83	6.7	0.5
Selling, General & Admin	4.97	7.3	5.82	5.75	4.98	3.21	1.11
Research & Development	6.96	14.67	12.84	10.37	12.45	4.92	2.63
Operating Expenses	11.93	21.97	18.66	16.12	17.44	8.13	3.73
Operating Income	-10.28	-20.52	-15.51	-12.24	-14.6	-1.42	-3.24
Interest Expense / Income	0.34	0.31	0.06	0.65	0.21	0.22	0.05
Other Expense / Income	-0.06	-0.03	-0.22	-0.04	-0.04	-	-
Pretax Income	-10.56	-20.8	-15.35	-12.86	-14.78	-1.64	-3.28
Net Income	-10.56	-20.8	-15.35	-12.86	-14.78	-1.64	-3.28
Shares Outstanding (Basic)	75	38	27	27	26	26	-
Shares Change	97.79%	42.03%	-0.07%	0.73%	-	-	-
EPS (Basic)	-0.14	-0.46	-0.45	-0.48	-0.56	-0.07	-0.25
EPS (Diluted)	-0.14	-0.46	-0.45	-0.48	-0.56	-0.07	-0.25
Free Cash Flow	-8	-16.44	-14.74	-12.24	-9.51	1.74	-2.14
Free Cash Flow Per Share	-12.81	-52.08	-66.31	-55.03	-43.08	7.89	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	-624.22%	-1420.12%	-491.74%	-315.62%	-515.38%	-21.25%	-647.15%
Profit Margin	-640.91%	-1439.78%	-486.85%	-331.48%	-521.61%	-24.54%	-656.22%
Free Cash Flow Margin	-485.67%	-1137.59%	-467.34%	-315.52%	-335.63%	26.00%	-428.19%
EBITDA	-9.91	-20.17	-14.94	-11.83	-14.23	-1.42	-3.22
EBITDA Margin	-601.76%	-1395.74%	-473.83%	-304.94%	-502.30%	-21.21%	-644.10%
Depreciation & Amortization	0.31	0.32	0.35	0.38	0.33	0	0.02
EBIT	-10.22	-20.49	-15.29	-12.21	-14.57	-1.42	-3.24
EBIT Margin	-620.33%	-1418.10%	-484.85%	-314.71%	-514.08%	-21.25%	-647.15%

Source: Financials are provided by Nasdaq Data Link and sourced from audited reports submitted to the Securities and Exchange Commission (SEC).